| Dr Danica Natasha Barron-dhillon, MD | |
|
1800 Versailles Ave, Alameda, CA 94501-1653 | |
| (510) 928-8400 | |
| Not Available |
| Full Name | Dr Danica Natasha Barron-dhillon |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 25 Years |
| Location | 1800 Versailles Ave, Alameda, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316025935 | NPI | - | NPPES |
| 00A744930 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A74493 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital Manteca | Manteca, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659450955 PECOS PAC ID: 1254244973 Enrollment ID: O20040113000757 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699885079 PECOS PAC ID: 1254244973 Enrollment ID: O20040113000784 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
| Entity Name | Eden Emergency Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891786240 PECOS PAC ID: 7012802333 Enrollment ID: O20040217000163 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Other Medical Care Group |
| Entity Identifiers | NPI Number: 1629301346 PECOS PAC ID: 1254244973 Enrollment ID: O20110318000170 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
| Entity Name | Big River Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033501168 PECOS PAC ID: 2466764303 Enrollment ID: O20150706002430 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
| Entity Name | Shasta Regional Emergency Medical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679007140 PECOS PAC ID: 0941587588 Enrollment ID: O20170508001882 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
| Entity Name | Emergency Physicians Associates San Jose Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306311576 PECOS PAC ID: 8921344292 Enrollment ID: O20190107003386 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Danica Natasha Barron-dhillon, MD 1800 Versailles Ave, Alameda, CA 94501-1653 Ph: (510) 928-8400 | Dr Danica Natasha Barron-dhillon, MD 1800 Versailles Ave, Alameda, CA 94501-1653 Ph: (510) 928-8400 |
News Archive
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
Today's news highlights include reports about signs of progress in the debt-reduction talks and details of a new study that finds Medicaid makes a big difference in people's lives.
Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.
› Verified 1 days ago
Antonio Domenico Muto-isolani, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2070 Clinton Ave, Alameda, CA 94501 Phone: 510-523-4357 | |
Dr. Arthur Howard Glaser, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2070 Clinton Ave, Alameda, CA 94501 Phone: 510-523-4357 | |
Eric Otani, M.D Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2070 Clinton Ave, Alameda, CA 94501 Phone: 510-523-4357 | |
Edward D Lee, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2070 Clinton Ave, Alameda, CA 94501 Phone: 510-523-4357 | |
Jordan Y Cohen, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2070 Clinton Ave, Alameda, CA 94501 Phone: 510-523-4357 | |
Henry William Turkel, M.D., MPH Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1342 Saint Charles St, Alameda, CA 94501 Phone: 510-896-9445 |